Health Care & Life Sciences » Pharmaceuticals | GreenPeptide Co. Ltd.

GreenPeptide Co. Ltd. | Income Statement

Fiscal year is April-March. All values JPY Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
933,388.00
821,625.00
822,556.00
529,612.00
354,410.00
155,808
Cost of Goods Sold (COGS) incl. D&A
780,225.00
766,716.00
771,750.00
528,184.00
318,622.00
153,472
Gross Income
153,163.00
54,909.00
50,806.00
1,428.00
35,788.00
2,336
SG&A Expense
180,968.00
547,095.00
1,039,556.00
1,114,978.00
1,597,520.00
1,696,499
EBIT
27,805.00
492,186.00
988,750.00
1,113,550.00
1,561,732.00
1,694,163
Unusual Expense
625.00
5,100.00
-
-
-
202,444
Non Operating Income/Expense
46,578.00
78,525.00
4,501.00
3,410.00
11,607.00
14,316
Pretax Income
19,412.00
408,432.00
992,977.00
1,116,928.00
1,573,292.00
1,880,529
Income Tax
1,927.00
4,003.00
1,487.00
5,071.00
5,124.00
3,788
Consolidated Net Income
17,485.00
412,435.00
994,464.00
1,122,000.00
1,578,417.00
1,884,318
Net Income
17,485.00
412,435.00
994,464.00
1,113,661.00
1,577,143.00
1,884,318
Net Income After Extraordinaries
17,485.00
412,435.00
994,464.00
1,113,661.00
1,577,143.00
1,884,318
Net Income Available to Common
17,485.00
412,435.00
994,464.00
1,113,661.00
1,577,142.00
1,884,318
EPS (Basic)
1.46
20.60
35.28
32.74
41.25
44.95
Basic Shares Outstanding
11,944.30
20,024.10
28,184.80
34,014.90
38,234.80
41,916.40
EPS (Diluted)
1.46
20.60
35.28
32.74
41.25
44.95
Diluted Shares Outstanding
11,944.30
20,024.10
28,184.80
34,014.90
38,234.80
41,916.40
EBITDA
24,176.00
483,384.00
969,446.00
1,070,843.00
1,488,522.00
1,611,393
Non-Operating Interest Income
14.00
129.00
274.00
33.00
46.00
1,762
Minority Interest Expense
-
-
-
8,339.00
1,274.00
-

About GreenPeptide Co.

View Profile
Address
Fukuoka Bio Incubation Center 402
Kurume Fukuoka 839
Japan
Employees -
Website http://www.brightpathbio.com
Updated 07/08/2019
BrightPath Biotherapeutics Co., Ltd. engages in the drug development business. It focuses on the development of cancer immunotherapies. Its product candidates are based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens.